Psoriasis is a recurrent and protracted inflammatory disease. Generalized erythema, plaques, and silvery scales on the surface mainly characterize its skin lesions. Biologics bring new hope to psoriasis patients. However, HIV infection is a major concern before receiving biologics. Here, we present a case of the efficacy and safety of Ixekizumab, an interleukin 17 inhibitor, in the treatment of psoriasis patients living with HIV (PPLHIV).
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11603802 | PMC |
| http://dx.doi.org/10.1186/s12981-024-00675-8 | DOI Listing |
Publication Analysis
Top Keywords
psoriasis patients
12
ixekizumab alternative
4
alternative hiv-positive
4
psoriasis
4
hiv-positive psoriasis
4
patients psoriasis
4
psoriasis recurrent
4
recurrent protracted
4
protracted inflammatory
4
inflammatory disease
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!